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adequately assess the possibility of regulation at points prior to HMG-CoA formation (6) . Evaluation of all reactions prior to MVA synthesis has suggested that feedback inhibition by dietary cholesterol involves both the reaction catalyzed by HMG-CoA reductase and the preceding reaction catalyzed by HMG-CoA condensing enzyme (3-hydroxy-3-methylglutaryl-CoA acetoacetyl-CoA lyase, EC 4.1.3.5) (7). However, inhibition of HMGCoA condensing enzyme was relatively small (approximately 50$) compared with inhibition of HMG-CoA reductase (greater than 90*) (7); furthermore, other workers, using different techniques, have concluded that cholesterol feeding has no effect on HMG-CoA condensing enzyme (3, 8) .
Oral administration of cholestyramine, an anion exchange resin, results in an interruption of the normal enterohepatic circulation of bile salts, an increase in the fecal excretion of bile acids and neutral steroids (9, 10) , and a reduction in the plasma cholesterol concentration in animals and man (9, 11) . However, prolonged interference with cholesterol reabsorption may be counteracted by increased endogenous cholesterol synthesis with no net change in tissue concentration (12, 13) . It is now clear that cholestyramine administration is associated with a marked enhancement in cholesterol synthesis, as shown by an accelerated rate of decay of plasma cholesterol specific activity after administration of radioactive cholesterol (10, 14, 15) and by a marked increase in [ 14 C]acetate incorporation into cholesterol following cholestyramine feeding (16) . Because cholestyramine decreases intestinal absorption of cholesterol, resulting in a compensatory increase in hepatic synthesis, administration of this agent was used to further explore feedback regulation of cholesterol biosynthesis.
Methods
Male Sprague-Dawley rats weighing 100-300 g were fed ground Purina rat chow (control) or ground chow with added cholestyramine 1 at a 1 CholestyTamine resin was generously supplied by Dr. C. L. Bendush of Mead Johnson Research Center, Evansville, Indiana. level of 3% of the diet. After 3-7 days of treatment, rats were killed by decapitation, their livers were rapidly removed and chilled, and slices or homogenate fractions were prepared. At the time of death, blood was collected in beakers containing heparin, plasma was separated by centrifugation, and plasma cholesterol was determined by the method of Zlatkis et al. (17) . The liver samples were added to 20 volumes of 10* KOH in 50S ethanol and refluxed for 4 hours. After cooling, the mixture was extracted twice with 2 volumes of hexane. The hexane was evaporated to dryness, and the cholesterol in the residue was measured by the colorimetric method of Zlatkis et al. (17) .
Slices Following incubation, slices were blotted and saponified, and cholesterol was extracted as described by Daly et al. (18) . Digitonide formation, washing, colorimetric analysis, and radioactive assay were performed as outlined by Kabara (19) . Incorporation of 14 C into MVA, fatty acids, and CO 2 was measured by methods previously detailed (20) . Content, incorporation of 14 C, and specific activity of acetoacetate were determined as previously described (6) .
Homogenates.-To localize the biochemical sites of action, cell-free preparations were used. Individual reactions between acetate and MVA were studied by using [ 14 All rats were fed chow with or without cholestyramine for 3 days. Values are means =• = BE; number of rats tested is given in parentheses. Statistical evaluations of t and probability were performed by standard methods (22) .
was present in all flasks, permitting continuous generation of [
14 C]HMG-CoA at the same rate.
Livers were prepared, minced, homogenized, and fractionated as previously outlined (6, 20) . Following fractionation, microsomes were suspended in 5 ml of 0.1 ITIM potassium phosphate buffer, pH 7.0, containing 30 mM nicotin amide, 1 mM dithiothreitol (Cleland's reagent), 0.4 mM ethylenediaminetetraacetic acid (EDTA), and 0.6 mM MgCI.,. Preparation and incubation of homogenate fractions and isolation, purification, and assay of HMG, MVA, and acetoacetate were performed by methods previously described (6) .
Since incorporation of 14 C into products may be influenced by dilution of intermediate pools by endogenous substrate, altered incorporation following cholestyramine treatment does not necessarily indicate an altered rate of synthesis. Accordingly, specific activities and net synthesis of HMG and MVA were determined indirectly by measuring the specific activity of acetoacetate as previously described (6) .
There was considerable variation from day to day in enzyme activity, as previously noted (7, 20) . However, on any single day, control rats had similar values, and differences within groups were insignificant compared with the large differences between control and cholestyTamine-treated rats. For each experiment, all rats were killed at the same time of day, and tissues were processed in an identical manner.
Materiak.-[ 1 *C]HMG anhydride and [ 14 C] HMG-CoA were prepared as described by Louw et al. (21) . Cholestyramine resin is the insoluble chloride salt of an anion exchange resin, a large polymer containing quaternary ammonium groups attached to a styrene-2« divinylbenzene skeleton. Other materials were prepared or obtained as previously described (6) .
Results
Cholestyramine administration at a level of 3% of the diet had no effect on weight gain. Plasma cholesterol concentration decreased in all treated rats, but this decrease was not significant in all cases. There were no significant changes in liver cholesterol concentration.
To study the overall pathway of cholesterol synthesis, as well as selected segments of the All rata were fed chow with or without cholestyramine for 3 days. Values are means number of rats tested is given in parentheses. 
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WHITE radioactivity in HMG (Fig. IB) ; this effect is presumably the result of increased HMG-CoA removal following enhanced HMG-CoA reductase activity. The relative roles of soluble and microsomal fractions in determining the effects of cholestyramine were examined more closely by combining microsomal and soluble fractions from control or cholestyramine-treated rats (Fig. 2) . When both fractions were from cholestyramine-fed rats, there was a marked increase in incorporation into MVA with a relatively small increase in incorporation into HMG. When microsomes from normal rats were present, addition of soluble fraction from cholestyramine-treated rats resulted in an increase in both HMG and MVA synthesis, indicating that HMG-CoA formation, dependent on the soluble fraction, was limiting subsequent MVA formation. Similarly, when microsomes from cholestyramine-treated rats were present, addition of soluble fraction from cholestyramine-treated rats led to a marked increase in MVA formation. Addition of microsomes from cholestyramine-treated rats resulted in decreased accumulation of radioactivity in HMG and increased MVA formation; this phenomenon occurred in the presence of soluble fraction from normal rats or soluble fraction from cholestyramine-treated rats.
To determine whether incorporation of labeled substrate into product was a reflection of product synthesis, the specific activity of acetoacetate was determined, permitting correction for dilution of intermediate pools.
Synthesis of HMG, MVA, and cholesterol was compared with incorporation of labeled substrate ( Table 5 ). The specific activity of acetoacetate formed by liver slices or homogenates was not influenced by cholestyramine treatment; consequently, increased incorporation of [ M C]acetate into products correlated with increased HMG, MVA, or cholesterol synthesis.
Discusiion
Cholestyramine, one of several pharmacologic agents used to decrease plasma cholesterol concentration in an attempt to prevent atherosclerosis (11, 23) , is considered one of the more effective drugs for treatment of type II hyperlipoproteinemia (24) . However, the decrease in plasma cholesterol concentration has not been impressive in many cases, and in some patients a hypocholesterolemic effect has not been obtained (10, 14, 25) .
Cholestyramine produces a negative cholesterol balance with increased excretion of endogenous neutral and acidic sterols (10, 14) . The increment in cholesterol excreted can come from newly synthesized cholesterol, necessitating an increased rate of synthesis, or it can result from a depletion of tissue or plasma cholesterol pools. An increased rate of turnover of body cholesterol has been found in patients following cholestyramine treatment (14) . The drug probably fails to induce a decrease in plasma cholesterol concentration in many patients, because the rate of cholesterol synthesis increases enough to compensate Values are means ± SE. Conditions are described in the text.
•Assay was performed with 10o,000-p soluble fraction of liver homogenates instead of the rat liver slices used when MVA or cholesterol synthesis was measured.
for the increased excretion (10) . In the present study, the compensatory increase in synthesis was sufficient to prevent changes in liver cholesterol concentration and to minimize changes in plasma cholesterol concentration.
As previously emphasized, earlier conclusions regarding sites of regulation of cholesterol synthesis were based on assumptions that may not be valid (6) . Other workers have shown that cholestyramine produces a twelvefold increase in incorporation of [ 14 C] acetate into hepatic cholesterol, with only a two-to threefold increase in ["CJMVA incorporation into cholesterol (16) . These studies measured incorporation, rather than synthesis; furthermore, they measured the effect on the entire pathway without localizing the site of regulation. If MVA formation other than the one catalyzed by HMG-CoA reductase.
The amount of HMG-CoA converted to MVA will depend not only on the activity of HMG-CoA reductase but on the quantity of HMG-CoA generated by earlier reactions. For several reasons, the reaction catalyzed by HMG-CoA reductase has been considered an appropriate regulatory step in sterol biosynthesis (2-7). However, insufficient consideration has been given to possible regulation at the preceding step involving condensation of acetyl-CoA and acetoacetyl-CoA to form HMG-CoA. This step might also be considered a logical control point on theoretical grounds (6): the reaction is irreversible and is uniquely situated, influencing the concentration of acetyl-CoA available for oxidation or fatty acid synthesis, the concentration of acetoacetyl-CoA available for ketone synthesis, and the concentration of HMG-CoA available for sterol synthesis. Furthermore, if HMG-CoA was not a significant precursor of acetoacetate, then the step catalyzed by HMG-CoA condensing enzyme would represent the first reaction beyond the last quantitatively significant branch point, and feedback inhibition at this point would be analogous to that in several bacterial systems (3, 6) .
The importance of HMG-CoA condensing enzyme has not been generally recognized. Using short-duration cholesterol feeding (10 hours), Shapiro and Rodwell (8) showed that there was no effect on HMG-CoA condensing enzyme, in contrast to effects previously 906 WHITE demonstrated with more prolonged cholesterol feeding (7). Siperstein and Fagan (3) were unable to demonstrate changes in incorporation of [ 14 C]acetate into HMG following cholesterol feeding and suggested that synthesis of HMG was unaffected by dietary cholesterol. However, the microsomal fraction containing HMG-CoA reductase was also present in their experiments so that HMG was not an end product. In the presence of microsomes, net accumulation of HMG-CoA depends on both the rate of HMG-CoA formation and the rate of reduction of HMGCoA to MVA, as previously discussed (6, 7) . This fact is well exemplified in the experiments shown in Figure 1 , in which cholestyramine treatment resulted in increased incorporation of [ 14 C] acetate into HMG when microsomes were absent and HMG was an end product but decreased incorporation into HMG when microsomes were present and cholestyramine treatment increased the rate of reduction of HMG-CoA to MVA several fold. The use of a single system containing both soluble and microsomal fractions will obscure changes in the rate of HMG-CoA generation. Under these circumstances, increased activity of HMG-CoA condensing enzyme will be associated with increased MVA formation, since any increment in HMG-CoA formed will be converted to MVA. In the absence of microsomes, HMG-CoA condensing enzyme activity is decreased by cholesterol feeding (7) and markedly increased by interruption of the enterohepatic circulation of cholesterol with a release of feedback inhibition of cholesterol synthesis.
Several workers have assayed HMG-CoA condensing enzyme by measuring acetoacetate formation (26) (27) (28) , based on the assumption that this reaction proceeds entirely via HMGCoA, as suggested by Lynen et al. (29) . However, it is now clear that acetoacetate can also be formed by acetoacetyl-CoA deacylation (30, 31) . The present study showed that the activity of HMG-CoA condensing enzyme, as measured directly, was markedly increased following cholestyramine, but there was no increase in acetoacetate formation, indicating that assays that rely on acetoacetate formation as a measure of HMG-CoA condensing enzyme are not valid.
Regulation of two key reactions in the pathway prior to MVA formation suggests synchronous influences analogous to those on groups of rate-limiting enzymes governing reactions in pathways of gluconeogenesis and glycolysis (32) . In addition, reactions beyond MVA may also be involved in regulation of cholesterol biosynthesis (33) . However, in contrast to the studies of Huff et al. (16) , no stimulation of the reaction pathway beyond MVA was found under the conditions of the present experiments. Since hypocholesterolemic effects of cholestyramine are attenuated by a compensatory increase in cholesterol biosynthesis, agents that will prevent increased activity of HMG-CoA condensing enzyme, HMGCoA reductase, or both should, if used concomitant] y with cholesryramine, produce an effect on plasma and tissue cholesterol pools more dramatic than that obtained with cholestyramine alone.
